H2O welcomes Power UP report

/in , /by

The H2O consortium wishes to reinforce the statements made in the EPFIA Power Up Report highlighting the challenges we must overcome to achieve resilient healthcare systems.

If we give patients ways to measure their outcomes in a standardized manner, this will not only improve their communications with their physicians but will also create a body of knowledge that will allow us all as a society to learn what worked and what did not and get better. It is often called a ‘learning healthcare system’.  And learning health care systems become resilient. They improve continuously, they incorporate the knowledge and they advance science.

We are very pleased that H2O initiative is included in the report as an example of the public and private sector working together to address these critical needs.

 

Key highlights

  • The POWER Up report outlines EFPIA’s positioning on what they are calling the POWER up priorities: People-centricity, Outcomes, Workforce empowerment, Efficiency and Resilience
  • The report also calls for investment in transformational tools – namely digitalisation and innovation that generates value for patients, health systems and society as a whole
  • The report is a rich source of data for each of these areas
  • The report also emphasizes the need to measure outcomes in a standardized and consistent way (as we are doing in H2O)

Accessing the report

ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.

About IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/

Legal notice
Privacy Policy
Cookies Policy

       




Health administrators, clinicians, and patients discuss their unique experiences... Study shows integration with health care systems remains critical to succes...